Ignite Creation Date:
2025-12-24 @ 3:06 PM
Ignite Modification Date:
2025-12-26 @ 4:31 AM
Study NCT ID:
NCT01196559
Status:
COMPLETED
Last Update Posted:
2015-02-18
First Post:
2010-09-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Ovarian Cancer
Sponsor:
The Catholic University of Korea
Organization:
Study Overview
Official Title:
A Phase II Study of Vinorelbine and Gemcitabine Combination In Platinum Resistant Recurrent Epithelial Ovarian/Fallopian Tube/ Primary Peritoneal Carcinoma.
Status:
COMPLETED
Status Verified Date:
2015-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the objective response rate and safety in platinum-resistant epithelial ovarian/fallopian tube/primary peritoneal cancer patients treated with vinorelbine and gemcitabine combination chemotherapy.
Detailed Description:
Other objectives of this study are to evaluate Progression-free survival and measure CA-125 response rate.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: